ORBi: Detailled Reference

Article (Scientific journals)

Traitement hormonal de la menopause: traitement hormonal substitutif classique ou tibolone?

Reginster, Jean-Yves

2002 • In Journal de Gynécologie, Obstétrique et Biologie de la Reproduction, 31 (6), p. 541-9

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/2014

PubMed
12407324

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Postmenopausal Hormonal Treatment Conventional Hormone Replacement Therapy or Tibolone Effects on Bone.pdf

Publisher postprint (51.33 kB)

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Abstract :

[en] OBJECTIVE: Our purpose was to review with critical analysis, data from randomized controlled clinical trials comparing the effects on bone of conventional hormone replacement therapy (HRT) and tibolone. Their respective effects on bone were also reviewed and summarized. Materials and methods. Medline via PubMed was searched using a combination of the following key words "tibolone, estrogens and bone" to identify all randomized controlled trials tibolone versus HRT (1960-2001). RESULTS: Six randomized controlled trials that have been carried out to compare effects of tibolone and conventional HRT on prevention of postmenopausal bone loss were identified. Only one of these trials has been performed with a correct methodology (double-blind and with an adequate duration). In this trial over 2 years, the highest significant increase from baseline in bone mineral density (BMD) at all sites was observed with HRT; in addition, HRT showed a significantly greater increase in BMD at lumbar spine than tibolone. Randomized placebo-controlled trials have demonstrated that tibolone produces positive effects on BMD. Nevertheless, no clinical convincing data are available to support its efficacy in the prevention of osteoporotic fractures. The positive impact on BMD of conventional HRT to prevent postmenopausal bone loss and to treat established osteoporosis has been shown by many randomized controlled trials. Regarding fracture risk prevention, some clinical and epidemiological data suggest that HRT initiated in early or late postmenopause may prevent fractures if it is administered at standard doses and continued for a long time. CONCLUSION: HRT is always the reference treatment of postmenopausal symptoms related to estrogen deficiency.

Disciplines :

Rheumatology

Author, co-author :

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

Language :

French

Title :

Traitement hormonal de la menopause: traitement hormonal substitutif classique ou tibolone?

Alternative titles :

[en] Postmenopausal Hormonal Treatment: Conventional Hormone Replacement Therapy or Tibolone? Effects on Bone

Publication date :

October 2002

Journal title :

Journal de Gynécologie, Obstétrique et Biologie de la Reproduction

ISSN :

0368-2315

eISSN :

1773-0430

Publisher :

Elsevier Masson, Paris, France

Volume :

31

Issue :

6

Pages :

541-9

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 01 December 2009

Statistics

Number of views

176 (0 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

6

Scopus citations^®
without self-citations

6

OpenAlex citations

5

Bibliography

Prelevic GM, Bartram C, Wood J, Okolo S, Ginsburg J. Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progestogen therapy in postmenopausal women. Gynecol Endocrinol 1996; 10: 413-20.
Stepan JJ, Schreiber V. Anabolic effects of progestogens in bone remodelling. Sb Lek 1995; 96: 293-7.
Lippuner K, Haenggi W, Birkhaeuser MH, Casez JP, Jaeger P. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17β-estradiol and dydrogesterone. J Bone Miner Res 1997; 12: 806-12.
Yang TS, Tsan SH, Chen CR, Chang SP, Yuan CC. Evaluation of conjugated estrogen plus medroxyprogesterone acetate versus tibolone in early postmenopausal Chinese women. Chin Med J (Taipei) 1999; 62: 308-15.
Castelo-Branco C, Vicente JJ, Figueras F, Sanjuan A, Martinez De Osaba MJ, Casals E, et al. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 2000; 34: 161-8.
Milner M, Harrison RF, Gilligan E, Kelly A. Bone density changes during two years treatment with tibolone or conjugated estrogens and norgestrel, compared with untreated controls in postmenopausal women. Menopause 2000; 7: 327-33.
Netelenbos JC, Siregar-Emck MTW, Schot LPC, Van Ginkel FC, Lips P, Leeuwenkamp OR. Short-term effects of Org OD 14 and 17β-oestradiol on bone and lipid metabolism in early post-menopausal women. Maturitas 1991; 13: 137-49.
Roux C, Pelissier C, Fechtenbaum J, Loisseau-Peres S, Benhamou CL. Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporos Int 2002; 13: 241-8.
Lindsay R, Hart DM, Kraszewski A. Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. Br Med J 1980; 280: 1207-9.
Rymer J, Chapman MG, Fogelman I. Effect of tibolone on postmenopausal bone loss. Osteoporosis Int 1994; 4: 314-9.
Rymer J, Robinson J, Fogelman I. Effects of 8 years of treatment with tibolone 2.5mg daily on postmenopausal bone loss. Osteoporos Int 2001; 12: 478-83.
Berning B, Van Kuijk C, Kuiper JW, Coelingh Bennink HJT, Kicovic PM, Fauser BC. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: A two-year randomized, placebo-controlled study. Bone 1996; 19: 395-9.
Beardsworth SA, Kearney CE, Purdie DW. Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: A two-year randomised controlled trial. Br J Obstet Gynaecol 1999; 106: 678-83.
Gallagher JC, Baylink DJ, Freeman R, McClung M. Prevention of bone loss with tibolone in postmenopausal women: Results of two randomized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab 2001; 86: 4717-26.
Lyritis GP, Karpathios S, Basdekis K, Grigoriou O, Katostaras T, Paspati I, et al. Prevention of post-oophorectomy bone loss with tibolone. Maturitas 1995; 22: 247-53.
Fogelman I, Bessent RG, Smith ML, Hart DM, Lindsay R. Assessment of synthetic steroid (Org OD 14): Effect on skeletal metabolism by 24-h whole-body retention of diphosphonate. Maturitas 1981; 3: 265-9.
Bjarnason NH, Bjarnason K, Haarbo J, Rosenquist C, Christiansen C. Tibolone: Prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab 1996; 81: 2419-22.
Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761-7.
Geusens P, Dequeker J, Gielen J, Schot LP. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis. Maturitas 1991; 13: 155-62.
Studd J, Arnala I, Kicovic PM, Zamblera D, Kroger H, Holland N. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures. Obstet Gynecol 1998; 92: 574-9.
Pavlov PW, Ginsburg J, Kicovic PM, Van Der Schaaf DB, Prelevic G, Coelingh Bennink HJ. Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures. Gynecol Endocrinol 1999; 13: 230-7.
Parviainen MT, Jaaskelainen K, Kroger H, Arnala I, Alhava E. Urinary bone resorption markers in monitoring treatment of symptomatic osteoporosis. Clin Chim Acta 1999; 279: 145-54.
Reginster JY, Agnusdei D, Gennari C, Kicovic PM. Association of tibolone and fluoride displays a pronounced effect on bone mineral density in postmenopausal osteoporotic women. Gynecol Endocrinol 1999; 13: 361-8.
Berning B, Bennink HJ, Fauser BC. Tibolone and its effects on bone: A review. Climacteric 2001; 4: 120-36.
Javaid MK, Cooper C. How to prevent fractures in the individual with osteoporosis. Best Pract Res Clin Rheumatol 2001; 15: 497-515.
Von Hoist T. Alternatives to hormone replacement therapy: Raloxifene and tibolone. Z Arztl Fortbild Qualitatssich 2000; 94: 205-9.
Consensus Development Conference: Prophylaxis and treatment of osteoporosis. Am J Med 1991; 90: 107-10.
European Menopause Society. European consensus development conference on menopause. Hum Reprod 1996; 11: 975-9.
Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, et al. American Association of Clinical Endocrinologists 2001 Medical Guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocr Pract 2001; 7: 293-312.
Dören M. An assessment of hormone replacement therapy to prevent postmenopausal osteoporosis. Osteoporos Int 1999; Suppl 2: S53-61.
Writing Group for the PEPI trial. Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial. J Am Med Assoc 1996; 276: 1389-96.
Lindsay R, Hart DM, Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 1984; 63: 759-63.
Lindsay R. The role of estrogen in the prevention of osteoporosis. Endocrinol Metab Clin North Am 1998; 27: 399-409.
Stevenson JC, Cust MP, Gangar KF, Hillard TC, Lees B, Whitehead MI. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postemenopausal women. Lancet 1990; 335: 265-9.
Palacios S, Menendez C, Jurado AR, Vargas JC. Effects of percutaneous oestradiol versus oral oestrogens on bone density. Maturitas 1995; 20: 209-13.
Hirvonen E, Cacciatore B, Wahlstrom T, Rita H, WilenRosenqvist G. Effects of transdermal oestrogen therapy in postmenopausal women: A comparative study of an oestradiol gel and an oestradiol delivering patch. Br J Obstet Gynaecol 1997; 104 (Suppl 16): 26-31.
Christiansen C, Lindsay R. Estrogens, bone loss and preservation. Osteoporos Int 1990; 1: 7-13.
Lees B, Pugh M, Siddle N, Stevenson JC. Changes in bone density in women starting hormone replacement therapy compared with those in women already established on hormone replacement therapy. Osteoporos Int 1995; 5: 344-8.
Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study. J Am Med Assoc 1997; 277: 543-7.
Munk-Jensen N, Pors Nielsen S, Obel EB, Bonne Eriksen P. Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: A double-blind placebo controlled study. Br Med J 1988; 296: 1150-2.
Delmas PD, Pornel B, Felsenberg D, Garnero P, Hardy P, Pilate C, et al. A dose-ranging trial of a matrix transdermal 17β-estradiol for the prevention of bone loss in early postmenopausal women. International Study Group. Bone 1999; 24: 517-23.
Mizunuma H, Okano H, Soda M, Kagami I, Miyamoto S, Tokizawa T, et al. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: A 2-year prospective study. Maturitas 1997; 27: 69-76.
Heikkinen J, Vaheri R, Kainulainen P, Timonen U. Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: A comparison of high- and low-dose estrogen-progestin regimens. Osteoporos Int 2000; 11: 929-37.
Ettinger B, Genant HK, Steiger P, Madvig P. Low-dosage micronized 17β-estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol 1992; 166: 479-88.
Stevenson JC, Teter P, Lees B. 17β-estradiol (1mg/day) continuously combined with dydrogesterone (5, 10 or 20mg/day) increases bone mineral density in postmenopausal women. Maturitas 2001; 38: 197-203.
Lees B, Stevenson JC. The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17β and dydrogesterone. Osteoporos Int 2001; 12: 251-8.
Bjarnason NH, Byrjalsen I, Hassager C, Haarbo J, Christiansen C. Low doses of estradiol in combination with gestodene to prevent early postmenopausal bone loss. Am J Obstet Gynecol 2000; 183: 550-60.
Evans SF, Davie MWJ. Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages. Clin Endocrinol 1996; 44: 79-84.
Weiss SR, Ellman H, Dolker M. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal Estradiol Investigator Group. Obstet Gynecol 1999; 94: 330-6.
Christiansen C, Riis BJ. 17β-estradiol and continuous norethisterone: A unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 1990; 71: 836-41.
Lindsay R, Tohme JF. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 1990; 76: 290-5.
Harris ST, Ericksen EF, Davidson M, Ettinger MP, Moffett AH, Baylink DJ, et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2001; 86: 1890-7.
Bone HJ, Greenspan SL, McKeever C, Bell N, Davidson M. Downs RW, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab 2000; 85: 720-6.
Recker RR, Davies KM, Dowd RM, Heaney RP. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial. Ann Intern Med 1999; 130: 897-904.
Lindsay R. The menopause and osteoporosis. Obstet Gynecol 1996; 87 (Suppl 2): S16-9.
Dören M, Samsioe G. Prevention of postmenopausal osteoporosis with oestrogen replacement therapy and associated compounds: Update on clinical trials since 1995. Hum Reprod Update 2000; 6: 419-26.
Blank RD, Bockman RS. A review of clinical trials of therapies for osteoporosis using fracture as an end point. J Clin Densitom 1999; 2: 435-52.
Hochberg M. Preventing fractures in postmenopausal women with osteoporosis. A review of recent controlled trials of antiresorptive agents. Drugs Aging 2000; 17: 317-30.
Grady D, Cummings SR. Postmenopausal hormone therapy for prevention of fractures. How good is the evidence? J Am Med Assoc 2001; 285: 2909-10.
Reginster JY, Bruyere O, Audran M, Avouac B, Body JJ, Bouvenot G, et al. Do estrogens effectively prevent osteoporosis-related fractures? Calcif Tissue Int 2000; 67: 191-4.
Naessen T, Persson I, Adami HO, Bergstrom R, Bergkvist L. Hormone replacement therapy and the risk for first hip fracture. A prospective, population-based cohort study. Ann Intern Med 1990; 113: 95-103.
Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980; 303: 1195-8.
Kanis JA, Johnell O, Gullberg B, Allander E, Dilsen G, Gennari C, et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. Br Med J 1992; 305: 1124-8.
Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995; 122: 9-16.
Cauley JA, Zmuda JM, Ensrud KE, Bauer DC, Ettinger B, Study of Osteoporotic Fractures Research Group. Timing of estrogen replacement therapy for optimal osteoporosis prevention. J Clin Endocrinol Metab 2001; 86: 5700-5.
Michaelsson K, Baron JA, Farahmand BY, Johnell O, Magnusson C, Persson PG, et al. Hormone replacement therapy and risk of hip fracture: Population based case-control study. The Swedish Hip Fracture Study Group. Br Med J 1998; 316: 1858-63.
Maxim P, Ettinger B, Spitalny GM. Fracture protection provided by long-term estrogen treatment. Osteoporos Int 1995; 5: 23-9.
Lafferty FW, Fiske ME. Postmenopausal estrogen replacement: A long-term cohort study. Am J Med 1994; 97: 66-77.
Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and biphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 1998; 104: 219-26.
Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117: 1-9.
Cauley JA, Black DM, Barrett-Connor E, Harris F, Shields K, Applegate W, et al. Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS). Am J Med 2001; 110: 442-50.
Komulainen MH, Kroger H, Tuppurainen MT, Heikkinen AM, Alhava E, Honkanen R, et al. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. Maturitas 1998; 31: 45-54.
Mosekilde L, Beck-Nielsen H, Sorensen OH, Nielsen SP, Charles P, Vestergaard P, et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women: Results of the Danish Osteoporosis Prevention Study. Maturitas 2000; 36: 181-93.
Windeler J, Lange S. Events per person year: A dubious concept. Br Med J 1995; 31: 454-6.
Torgerson DJ, Bell-Syer SEM. Hormone replacement therapy and prevention of nonvertebral fractures. J Am Med Assoc 2001; 285: 2891-7.

Similar publications